INSM
INSMED INCORPORATEDMarquee-fund ownership over time
This quarter's activity
New positions opened
Positions exited
None.
Current holders
Sorted by tenure (longest first)| Fund | First disclosed | Held | Entry price | Latest close | Return on entry |
|---|---|---|---|---|---|
| Duquesne Family Office re-entered | Q3 2020 | 24Q | $27 | $107 | +303% |
| Citadel Advisors re-entered | Q3 2024(8Q snapshot) | 7Q | $0.00 | $107 | — |
| Two Sigma Investments | Q3 2024(8Q snapshot) | 7Q | $75 | $107 | +43% |
| D.E. Shaw re-entered | Q3 2024(8Q snapshot) | 7Q | $0.00 | $107 | — |
| AQR Capital Management | Q3 2024(8Q snapshot) | 7Q | $75 | $107 | +43% |
| Millennium Management re-entered | Q3 2024(8Q snapshot) | 7Q | $0.00 | $107 | — |
| Renaissance Technologies re-entered | Q1 2025(8Q snapshot) | 5Q | $79 | $107 | +36% |
| Bridgewater Associates | Q2 2026 | 1Q | $109 | $107 | -2% |
“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.
Past holders
Funds that exited at some point| Fund | Last entry | Exited | Entry → Exit | Return |
|---|---|---|---|---|
| Point72 Asset Management 3× in & out | Q3 2025 | Q1 2026 | → $151 | +18% |
| Maverick Capital | Q2 2025 | Q1 2026 | → $149 | +121% |
| Soros Fund Management | Q3 2024 | Q3 2025 | → $128 | +71% |
| Viking Global Investors | Q3 2024 | Q4 2024 | → $71 | -5% |
Insider activity
Form 4 — officers, directors, 10%+ ownersFiled within two business days of each transaction by anyone with material insider status at INSMED Inc. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.
30d / 90d windows measured from Jun 5, 2026 — the most recent Form 4 on file — not from today.
- Form 40001685904-26-000012Jun 5, 2026
- Form 40001604019-26-000010Jun 5, 2026
- Form 40001870278-26-000017Jun 5, 2026
- Form 40001402051-26-000032Jun 5, 2026
- Form 40001796960-26-000016Jun 5, 2026
- Form 40001870278-26-000015May 22, 2026
- Form 40001402051-26-000030May 20, 2026
- Form 40001604019-26-000008May 15, 2026
- Form 40001272181-26-000004May 15, 2026
- Form 40001685904-26-000010May 15, 2026
- Form 40001758247-26-000002May 15, 2026
- Form 40001796960-26-000014May 15, 2026
- Form 40001870278-26-000012May 15, 2026
- Form 40001182633-26-000008May 15, 2026
- Form 40001609305-26-000004May 15, 2026
Fundamentals
XBRL · INSMED INCORPORATEDAnnual figures sourced directly from INSMED INCORPORATED's 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.
Recent SEC filings
10-K · 10-Q · 8-K · 13D/G · proxyThe most recent material filings for INSMED Inc — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.
- 8-KMaterial eventMay 15, 2026
- 8-KMaterial eventMay 7, 2026
- 10-QQuarterly reportMay 7, 2026
- 8-KMaterial eventApr 7, 2026
- DEF 14AProxy statementApr 1, 2026
- 8-KMaterial eventMar 23, 2026
- 10-KAnnual reportFeb 19, 2026
- 8-KMaterial eventFeb 19, 2026
- 8-KMaterial eventJan 9, 2026
- 8-KMaterial eventDec 17, 2025
- 8-KMaterial eventNov 18, 2025
- 10-QQuarterly reportOct 30, 2025
- 8-KMaterial eventOct 30, 2025
- 8-KMaterial eventAug 12, 2025
- 8-KMaterial eventAug 7, 2025
Trade history
Every open→close lifecycle across tracked funds| Fund | Open date | Close date | Open price | Close price / current | Return |
|---|---|---|---|---|---|
| Bridgewater Associates | Q2 2026 | open | $109 | $101 | -7% |
| Point72 Asset Management | Q3 2025 | Q1 2026 | $128 | $151 | +18% |
| Renaissance Technologies | Q3 2025 | open | $123 | $107 | -13% |
| Maverick Capital | Q2 2025 | Q1 2026 | $67 | $149 | +121% |
| Renaissance Technologies | Q1 2025 | Q2 2025 | $79 | $66 | -17% |
| Citadel Advisors | Q3 2024 | Q4 2024 | $0.00 | — | +0% |
| Citadel Advisors | Q3 2024 | open | $75 | $107 | +43% |
| Soros Fund Management | Q3 2024 | Q3 2025 | $75 | $128 | +71% |
| Two Sigma Investments | Q3 2024 | open | $75 | $107 | +43% |
| Viking Global Investors | Q3 2024 | Q4 2024 | $75 | $71 | -5% |
| D.E. Shaw | Q3 2024 | Q3 2025 | $0.00 | — | +0% |
| D.E. Shaw | Q3 2024 | open | $75 | $107 | +43% |
| AQR Capital Management | Q3 2024 | open | $75 | $107 | +43% |
| Millennium Management | Q3 2024 | Q3 2025 | $0.00 | — | +0% |
| Millennium Management | Q3 2024 | open | $75 | $107 | +43% |
| Duquesne Family Office | Q3 2024 | open | $75 | $107 | +43% |
| Point72 Asset Management | Q3 2024 | Q4 2024 | $0.00 | — | +0% |
| Point72 Asset Management | Q3 2024 | Q1 2025 | $75 | $79 | +6% |
| Duquesne Family Office | Q3 2020 | Q4 2020 | $27 | $37 | +38% |
- Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
- Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
- “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
- Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
- Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.